ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
Studies data on new anticoagulants, direct oral thrombin inhibitor (dabigatran) and direct inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial fibrillation are presented. Effects of these drugs on cardiovascular events in atrial fibrillation are analyz...
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Столичная издательская компания
2015-09-01
|
| coleção: | Рациональная фармакотерапия в кардиологии |
| Assuntos: | |
| Acesso em linha: | https://www.rpcardio.online/jour/article/view/283 |
| _version_ | 1826949915514765312 |
|---|---|
| author | Z. M. Safiullina S. V. Shalaev |
| author_facet | Z. M. Safiullina S. V. Shalaev |
| author_sort | Z. M. Safiullina |
| collection | DOAJ |
| description | Studies data on new anticoagulants, direct oral thrombin inhibitor (dabigatran) and direct inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial fibrillation are presented. Effects of these drugs on cardiovascular events in atrial fibrillation are analyzed based on the results of various studies. Prospects for further research are discussed. |
| first_indexed | 2024-03-08T14:06:22Z |
| format | Article |
| id | doaj.art-d14f30b7940048cd8a93b2e4453bd636 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2025-02-17T22:22:31Z |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-d14f30b7940048cd8a93b2e4453bd6362024-12-04T11:48:01ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-019217117610.20996/1819-6446-2013-9-2-171-176283ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGESZ. M. Safiullina0S. V. Shalaev1Tyumen State Medical AcademyTyumen State Medical Academy; Cardiology Clinic, Tyumen Regional Clinical Hospital №1Studies data on new anticoagulants, direct oral thrombin inhibitor (dabigatran) and direct inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial fibrillation are presented. Effects of these drugs on cardiovascular events in atrial fibrillation are analyzed based on the results of various studies. Prospects for further research are discussed.https://www.rpcardio.online/jour/article/view/283anticoagulantsdirect oral thrombin inhibitordirect inhibitor of coagulation factor xa |
| spellingShingle | Z. M. Safiullina S. V. Shalaev ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES Рациональная фармакотерапия в кардиологии anticoagulants direct oral thrombin inhibitor direct inhibitor of coagulation factor xa |
| title | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES |
| title_full | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES |
| title_fullStr | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES |
| title_full_unstemmed | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES |
| title_short | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES |
| title_sort | era of new anticoagulants in the treatment of non valvular atrial fibrillation prospects and challenges |
| topic | anticoagulants direct oral thrombin inhibitor direct inhibitor of coagulation factor xa |
| url | https://www.rpcardio.online/jour/article/view/283 |
| work_keys_str_mv | AT zmsafiullina eraofnewanticoagulantsinthetreatmentofnonvalvularatrialfibrillationprospectsandchallenges AT svshalaev eraofnewanticoagulantsinthetreatmentofnonvalvularatrialfibrillationprospectsandchallenges |